Active
Spikevax
Moderna's original COVID-19 mRNA vaccine (mRNA-1273), the product that validated mRNA vaccines at global scale. Now sold as a seasonal respiratory vaccine and the company's largest historical revenue driver.
ModernamRNA-1469
In Development
Investigational mRNA vaccine candidate against Bundibugyo ebolavirus. On Nov. 4, 2026 Moderna said WHO's Technical Advisory Group on Candidate Vaccine Prioritization recommended it for the Phase 2/3 Tumaini study in the Democratic Republic of the Congo after an Oct. 22 review. The study uses a ring-vaccination design and is co-sponsored by the Institut National de Recherche Biomedicale and the University of Antwerp. There is no licensed vaccine specifically indicated for Bundibugyo virus disease.
Latest update Nov 6, 2026
01
Current status
Entry still requires regulatory approval, and Moderna named no start date. Interim Phase 1 results in healthy adults ages 18 to 65 in Canada showed the shot was generally well tolerated and a single dose generated binding antibodies. CEPI has committed up to $58.5 million for preclinical testing, Phase 1 trials in Canada and Uganda, and additional clinical doses. CEPI's separate funding for the Tumaini study is not part of that commitment.
02
In the news1
WHO advisers recommend Moderna's Bundibugyo shot for trial
On Nov. 4, 2026, WHO Director-General Tedros Adhanom Ghebreyesus said expert groups are recommending that Moderna's mRNA-1469 be added to the Tumaini trial against Bundibugyo virus in the Democratic Republic of the Congo. Moderna said the recommendation followed an Oct. 22 review by WHO's Technical Advisory Group and that the candidate still needs regulatory approval before it joins the study. Moderna also said interim Phase 1 results in healthy adults in Canada showed the shot was generally well tolerated and that a single dose produced binding antibodies, and that CEPI has committed up to $58.5 million for preclinical work, Phase 1 trials, and extra clinical doses.
03
More from Moderna6
- Active
mRESVIA
mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) - the first mRNA vaccine approved for a disease other than COVID-19, and a key pillar of Moderna's expanding respiratory franchise.
- Active
mFlusiva
Moderna's standalone mRNA seasonal influenza vaccine (mRNA-1010), the fourth product in its respiratory franchise alongside Spikevax, mRESVIA, and mCOMBRIAX.
- In Development
Intismeran autogene (mRNA-4157)
An individualized neoantigen cancer therapy, co-developed with Merck, that is custom-manufactured for each patient's tumor mutations and given with KEYTRUDA to train the immune system against the cancer. It is Moderna's highest-value pipeline asset.
- Active
mCOMBRIAX
Moderna's combination COVID-19 and influenza vaccine (mRNA-1083), the world's first authorized flu-plus-COVID combination vaccine, delivered as a single shot.
- In Development
mRNA-4194 (INTERCEPT-Lynch)
An investigational mRNA cancer-prevention vaccine, developed with the University of Oxford, designed to generate immune responses against early cancer-development targets in people with Lynch syndrome - Moderna's first program aimed at preventing cancer before it develops rather than treating existing disease.
04
More in Biotech
In DevelopmentAurora Powerhouse
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
In DevelopmentFuel Recycling
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Early CommercializationAtomic Alchemy Isotope Platform
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
In DevelopmentNatrium
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.